NEXT SCIENCE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.315 AUD | -5.97% |
|
-17.11% | -7.35% |
| May. 03 | Transcript : Next Science Limited - Shareholder/Analyst Call | |
| Apr. 24 | Next Science Product Sales Rise 19% to $5.5 Million for March Quarter | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 238.3 | 186.8 | 178.9 | 100.2 | 67.54 | 61.42 | - | - |
| Enterprise Value (EV) 1 | 221.9 | 171.7 | 171.9 | 96.35 | 59.22 | 48.67 | 56.4 | 55.62 |
| P/E ratio | -15.2 x | -15.1 x | -19 x | -7.74 x | -3.33 x | -4.31 x | -10.3 x | -31.2 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 58.7 x | 54.3 x | 20 x | 8.56 x | 3.04 x | 1.88 x | 1.51 x | 1.22 x |
| EV / Revenue | 54.6 x | 49.9 x | 19.2 x | 8.23 x | 2.67 x | 1.49 x | 1.39 x | 1.1 x |
| EV / EBITDA | -18.6 x | -14.9 x | -19.8 x | -8.16 x | -3.99 x | -4.06 x | -8.57 x | -92.8 x |
| EV / FCF | -17.5 x | -14.2 x | -19.1 x | -7.86 x | -3.71 x | -3.08 x | - | - |
| FCF Yield | -5.73% | -7.06% | -5.23% | -12.7% | -26.9% | -32.5% | - | - |
| Price to Book | 12.3 x | 9.87 x | 16.5 x | 12.2 x | 4.23 x | 6.21 x | 11.2 x | 7.8 x |
| Nbr of stocks (in thousands) | 180,710 | 194,201 | 197,974 | 214,790 | 291,695 | 291,695 | - | - |
| Reference price 2 | 1.319 | 0.9617 | 0.9039 | 0.4667 | 0.2315 | 0.2106 | 0.2106 | 0.2106 |
| Announcement Date | 2/28/20 | 2/21/21 | 2/22/22 | 2/27/23 | 1/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.061 | 3.441 | 8.948 | 11.71 | 22.2 | 32.71 | 40.67 | 50.54 |
| EBITDA 1 | -11.94 | -11.49 | -8.686 | -11.81 | -14.84 | -11.98 | -6.582 | -0.5991 |
| EBIT 1 | -12.5 | -12.19 | -9.476 | -12.7 | -15.95 | -12.88 | -7.913 | -2.063 |
| Operating Margin | -307.85% | -354.2% | -105.91% | -108.45% | -71.87% | -39.39% | -19.46% | -4.08% |
| Earnings before Tax (EBT) 1 | -14.35 | -11.91 | -9.35 | -12.68 | -16.27 | -14.8 | - | - |
| Net income 1 | -14.35 | -11.91 | -9.35 | -12.68 | -16.27 | -13.28 | -8.713 | -2.863 |
| Net margin | -353.42% | -346.18% | -104.49% | -108.29% | -73.29% | -40.61% | -21.43% | -5.66% |
| EPS 2 | -0.0865 | -0.0636 | -0.0475 | -0.0603 | -0.0695 | -0.0489 | -0.0205 | -0.006750 |
| Free Cash Flow 1 | -12.71 | -12.12 | -8.981 | -12.27 | -15.94 | -15.8 | - | - |
| FCF margin | -312.9% | -352.22% | -100.37% | -104.72% | -71.82% | -48.31% | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/20 | 2/21/21 | 2/22/22 | 2/27/23 | 1/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2023 S1 |
|---|---|---|---|---|---|---|
| Net sales | 1.054 | 2.387 | 3.915 | 5.033 | 5.411 | - |
| EBITDA | -6.529 | - | - | -4.92 | -6.4 | - |
| EBIT | -6.873 | -5.315 | - | -5.21 | -6.583 | - |
| Operating Margin | -652.08% | -222.66% | - | -103.52% | -121.65% | - |
| Earnings before Tax (EBT) | -6.695 | - | - | -5.151 | -6.589 | - |
| Net income 1 | -6.695 | - | - | -5.151 | -6.589 | -8.613 |
| Net margin | -635.21% | - | - | -102.34% | -121.76% | - |
| EPS 2 | - | - | - | - | - | -0.0401 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/25/20 | 2/21/21 | 8/29/21 | 2/22/22 | 8/24/22 | 8/30/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 16.4 | 15.1 | 7.09 | 3.89 | 8.31 | 12.7 | 5.02 | 5.8 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -12.7 | -12.1 | -8.98 | -12.3 | -15.9 | -15.8 | - | - |
| ROE (net income / shareholders' equity) | -145% | -62.2% | -63% | - | -156% | -82.3% | - | - |
| ROA (Net income/ Total Assets) | -86.1% | -51.4% | -50.1% | -96.9% | -107% | -57.7% | - | - |
| Assets 1 | 16.66 | 23.17 | 18.68 | 13.09 | 15.18 | 23.02 | - | - |
| Book Value Per Share 2 | 0.1100 | 0.1000 | 0.0500 | 0.0400 | 0.0500 | 0.0300 | 0.0200 | 0.0300 |
| Cash Flow per Share 2 | -0.0700 | -0.0600 | -0.0400 | -0.0600 | -0.0600 | -0.0300 | -0.0200 | -0 |
| Capex 1 | 0.37 | 0.21 | 0.72 | 0.48 | 0.88 | 0.54 | 0.11 | 0.13 |
| Capex / Sales | 9.23% | 6.2% | 8.01% | 4.06% | 3.98% | 1.66% | 0.26% | 0.26% |
| Announcement Date | 2/28/20 | 2/21/21 | 2/22/22 | 2/27/23 | 1/29/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.2106
USD
Average target price
0.2415
USD
Spread / Average Target
+14.69%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.35% | 61.42M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- NXS Stock
- Financials Next Science Limited
